OPN 6602
Alternative Names: OPN-6602Latest Information Update: 18 Feb 2025
At a glance
- Originator Plexxikon
- Developer Opna Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action CREB-binding protein inhibitors; EP300 protein modulators; Histone acetyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple myeloma
- Preclinical Leukaemia; Prostate cancer
Most Recent Events
- 12 Feb 2025 OPN 6602 receives Orphan Drug status for Multiple myeloma in USA
- 12 Feb 2025 Opna Bio plans a further studies for Multiple myeloma (Combination therapy)
- 07 Dec 2024 Pharmacodynamics and adverse events data from a preclinical trial in Multiple myeloma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-HEM 2024)